Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial

Critical Care Medicine

Volumn 27, Issue 8, 1999, Pages 1478-1485

  Abraham, Edward ^a,l   Baughman, Robert ^b   Fletcher, Eugene ^c   Heard, Stephen ^d   Lamberti, James ^e   Levy, Howard ^f   Nelson, Loren ^g   Rumbak, Mark ^h   Steingrub, Jay ⁱ   Taylor, James ^j   Park, Youn C ^k   Hynds, Jeri Matera ^k   Freitag, Jeffrey ^k  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g Orlando Regional Health Center   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ BAYSTATE MEDICAL CENTER   (United States)

^j St Joseph Hospital Tacoma   (United States)

^k Liposome Company Incorporated   (United States)

^l UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Liposomal prostaglandin E1; Liposomes; Mechanical ventilation; Neutrophils; Oxygenation; Prostaglandin E1

Indexed keywords

LIPOPROSTAGLANDIN E1; PROSTAGLANDIN E1; DRUG CARRIER; LIPOSOME; VASODILATOR AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; HYPOXIA; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; ANOXIA; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDY; TIME;

ADULT; AGED; ALPROSTADIL; ANOXIA; DOUBLE-BLIND METHOD; DRUG CARRIERS; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVAL ANALYSIS; TIME FACTORS; VASODILATOR AGENTS; VENTILATOR WEANING;

EID: 0032839332     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199908000-00013     Document Type: Article

References (21)

1. 1. Repine JE: Scientific perspectives on adult respiratory distress syndrome. Lancet 1992; 339:466-469
2. 2. Chollet-Martin S, Jourdain B, Gibert C, et al: Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med 1996; 154:594-601
3. 3. Mulligan MS, Paulson JC, Frees SD, et al: Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 1993; 364:149-151
4. 4. Doerschuk CM, Quinlan WM, Doyle NA, et al: The role of P-selectin and ICAM-1 in acute lung injury as determined using blocking antibodies and mutant mice. J Immunol 1996; 157:4609-4614
5. 5. Till GO, Johnson KJ, Kunkel R, et al: Intravascular activation of complement and acute lung injury: Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest 1982; 69:1126-1133
6. 6. Eierman DF, Yagami M, Erme SM, et al: Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci U S A 1995; 92:2815-2819
7. 1. Prostaglandins 1994; 48:187-195
8. 1 (TLC C-53) immediately prior to reperfusion in a two-hour canine infarct/ reperfusion model. J Am Coll Cardiol 1995; Feb:248A
9. 9. Janoff, A: Integrin-mediated targeting of opsonized liposomes to human endothelial cells and phagocytes: a paradigm for new therapies. In: Liposome Advances: Progress in Drug and Vaccine Development. London, 1996, p A9
10. 10. Janoff A: Integrin-mediated targeting of opsonized liposomes to human endothelial cells and phagocytes: A paradigm for new therapies. In: NATO Advanced Studies Institute: Targeting of Drugs. Capa Sorinion Beach, Greece, 1997, A14
11. 1 in a canine thrombolysis model. J Am Coll Cardiol 1994; 24: 1382-1390
12. 1 posttreatment decreases IL-1-induced neutrophil accumulation and lung leak in rats. J Appl Physiol 1994; 76:151-157
13. 1 in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996; 24:10-15
14. 14. Bernard GR, Artigas A, Brigham KL, et al: The American-European consensus conference on ARDS. Am J Respir Crit Care Med 1994; 149:818-824
15. 15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-828
16. 16. Murray JF, Matthay MA, Luce JM, et al: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138:720-723
17. 17. Yang KL, Tobin MJ: A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med 1991; 324:1445-1450
18. 18. Dellinger RP, Zimmerman JL, Hyers TM, et al: Inhaled nitric oxide in ARDS: preliminary results of a multicenter clinical trial. Crit Care Med 1996; 24:A29
19. 19. Anzueto A, Baughman RP, Guntupalli KK, et al: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334: 1417-1421
20. 20. Zeni F, Freeman B, Natanson C: Antiinflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
21. 21. Chesnutt AN, Matthay MA, Tibayan F, et al: Early detection of type III procollagen peptide in acute lung injury: Pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997; 156:840-845